AR109033A2 - Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso - Google Patents
Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su usoInfo
- Publication number
- AR109033A2 AR109033A2 ARP170101938A ARP170101938A AR109033A2 AR 109033 A2 AR109033 A2 AR 109033A2 AR P170101938 A ARP170101938 A AR P170101938A AR P170101938 A ARP170101938 A AR P170101938A AR 109033 A2 AR109033 A2 AR 109033A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- radicals
- compounds
- benzotiepina
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 15
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 229910052731 fluorine Inorganic materials 0.000 abstract 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- -1 COO-C1− alkyl 6 Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/02—Acyclic radicals
- C07H7/027—Keto-aldonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Un compuesto que tiene la fórmula (1) en la que los significados son, X es O, NH, CH₂ o un enlace; R¹ es alquilo C₁₋₆; R², R², R³, R³, R⁴, R⁴, R⁵, R⁵ son, independientemente unos de otros, H, Cl, Br, I, OH, -(CH₂)-OH, CF₃, NO₂, N₃, CN, S(O)ₚ-R⁶, O-S(O)ₚ-R⁶, alquilen C₁₋₆-S(O)ₚ-R⁶, alquilen C₁₋₆-O-S(O)ₚ-R⁶, COOH, COO-alquilo C₁₋₆, CONH₂, CONH-alquilo C₁₋₆, CON[alquilo C₁₋₆]₂, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, O-alquilo C₁₋₆, donde uno, más de uno o todos los hidrógenos en los radicales alquilo pueden estar reemplazados con flúor; fenilo, -(CH₂)-fenilo, -(CH₂)ₙ-fenilo, O-fenilo, O-(CH₂)ₘ-fenilo, -(CH₂)-O-(CH₂)ₘ-fenilo, donde el anillo fenilo puede estar sustituido 1 a 3 veces con F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃, O-alquilo C₁₋₆, alquilo C₁₋₆, NH₂, NH-alquilo C₁₋₆, N(alquilo C₁₋₆)₂, SO₂-CH₃, COOH, COO-alquilo C₁₋₆, CONH₂; donde siempre por lo menos uno de los radicales R², R², R³, R³, R⁴, R⁴, R⁵, R⁵ tiene el significado de -O-(CH₂)ₘ-fenilo o -(CH₂)-O-(CH₂)ₘ-fenilo, donde el anillo fenilo puede estar sustituido 1 a 3 veces con F, Cl, Br, I, OH, CF₃, NO₂, CN, OCF₃, O-alquilo C₁₋₆, alquilo C₁₋₆, NH₂, NH-alquilo C₁₋₆, N(alquilo C₁₋₆)₂, SO₂-CH₃, COOH, COO-alquilo C₁₋₆, CONH₂; R⁶ es H, OH, alquilo C₁₋₆, NH₂, NH-alquilo C₁₋₆, N(alquilo C₁₋₆)₂; n es 2, 3, 4, 5, 6; m es 1, 2, 3, 4, 5, 6; p es 0, 1, 2; y sus sales farmacéuticamente aceptables, método para su preparación, productos farmacéuticos que comprenden estos compuestos y su uso. Reivindicación 12: Un compuesto caracterizado porque tiene la fórmula (2), (3) ó (4), y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006053635A DE102006053635B4 (de) | 2006-11-14 | 2006-11-14 | Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR109033A2 true AR109033A2 (es) | 2018-10-24 |
Family
ID=39092812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105027A AR063786A1 (es) | 2006-11-14 | 2007-11-12 | Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso |
| ARP170101938A AR109033A2 (es) | 2006-11-14 | 2017-07-12 | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105027A AR063786A1 (es) | 2006-11-14 | 2007-11-12 | Derivados de 1,4 -benzotiepina-1,1 dioxido sustituidos con radicales bencilo, productos farmaceuticos que comprenden estos compuestos y su uso |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US7956085B2 (es) |
| EP (1) | EP2084172B1 (es) |
| JP (1) | JP5301453B2 (es) |
| KR (1) | KR101489168B1 (es) |
| CN (1) | CN101535326B (es) |
| AR (2) | AR063786A1 (es) |
| AT (1) | ATE492554T1 (es) |
| AU (1) | AU2007321496B2 (es) |
| BR (1) | BRPI0718813B8 (es) |
| CA (2) | CA2865332C (es) |
| CL (1) | CL2007003262A1 (es) |
| CO (1) | CO6190534A2 (es) |
| CR (1) | CR10733A (es) |
| CY (1) | CY1111166T1 (es) |
| DE (2) | DE102006053635B4 (es) |
| DK (1) | DK2084172T3 (es) |
| EC (1) | ECSP099327A (es) |
| ES (1) | ES2358371T3 (es) |
| GT (1) | GT200900125A (es) |
| HR (1) | HRP20110197T1 (es) |
| IL (1) | IL198718A (es) |
| MA (1) | MA30883B1 (es) |
| MX (1) | MX2009003958A (es) |
| MY (1) | MY148429A (es) |
| NI (1) | NI200900076A (es) |
| NO (2) | NO342236B1 (es) |
| NZ (1) | NZ576762A (es) |
| PE (1) | PE20081493A1 (es) |
| PL (1) | PL2084172T3 (es) |
| PT (1) | PT2084172E (es) |
| RU (1) | RU2456282C2 (es) |
| SI (1) | SI2084172T1 (es) |
| SV (1) | SV2009003216A (es) |
| TN (1) | TN2009000180A1 (es) |
| TW (1) | TWI414530B (es) |
| UY (1) | UY30709A1 (es) |
| WO (1) | WO2008058628A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US8461312B2 (en) * | 2008-05-02 | 2013-06-11 | Sanofi | Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives |
| WO2010062861A2 (en) | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| EP2575821B1 (en) * | 2010-05-26 | 2015-08-12 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| EP2612669A4 (en) | 2010-08-31 | 2014-05-14 | Snu R&Db Foundation | USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST |
| AU2011326871B2 (en) | 2010-11-04 | 2015-02-12 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2852957C (en) * | 2011-10-28 | 2020-08-04 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| JP6217938B2 (ja) | 2011-10-28 | 2017-10-25 | ルメナ ファーマシューティカルズ エルエルシー | 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤 |
| JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
| KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
| EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
| JP6954926B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
| WO2019032026A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE |
| JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| EP3802504B1 (en) | 2018-06-05 | 2023-01-18 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| MX2020013839A (es) | 2018-06-20 | 2021-03-25 | Albireo Ab | Formulacion farmaceutica de odevixibat. |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| CN112638944A (zh) | 2018-08-23 | 2021-04-09 | 西进公司 | 抗tigit抗体 |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| DK3921028T3 (da) | 2019-02-06 | 2023-01-23 | Albireo Ab | Benzothiadiazepinforbindelser og anvendelse deraf som galdesyremodulatorer |
| BR112021015815A2 (pt) | 2019-02-12 | 2022-01-18 | Mirum Pharmaceuticals Inc | Métodos para tratar colestase |
| JP7695242B2 (ja) | 2019-12-04 | 2025-06-18 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| CN114786772B (zh) | 2019-12-04 | 2024-04-09 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| CN114761080B (zh) | 2019-12-04 | 2024-07-23 | 阿尔比里奥公司 | 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| JP7748451B2 (ja) | 2020-08-03 | 2025-10-02 | アルビレオ・アクチボラグ | ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用 |
| EP4243831A1 (en) | 2020-11-12 | 2023-09-20 | Albireo AB | Odevixibat for treating progressive familial intrahepatic cholestasis (pfic) |
| KR20230117393A (ko) | 2020-12-04 | 2023-08-08 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도 |
| TW202313579A (zh) | 2021-06-03 | 2023-04-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
| EP4511038A1 (en) | 2022-04-22 | 2025-02-26 | Albireo AB | Subcutaneous administration of an asbt inhibitor |
| CA3257752A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
| JP2025539895A (ja) | 2022-12-09 | 2025-12-09 | アルビレオ・アクチボラグ | 腎臓の疾患の治療におけるａｓｂｔ阻害剤 |
| CN121175041A (zh) * | 2023-05-19 | 2025-12-19 | 米鲁姆制药公司 | 包含2,3,4,5-四氢-苯并噻庚环-1,1-二氧化物衍生物的药物组合物和其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994391A (en) * | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US6221897B1 (en) * | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
| DE19825804C2 (de) * | 1998-06-10 | 2000-08-24 | Aventis Pharma Gmbh | 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| WO2003018024A1 (de) * | 2001-08-22 | 2003-03-06 | Aventis Pharma Deutschland Gmbh | Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung |
| GB0121621D0 (en) * | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
| US6740663B2 (en) | 2001-11-02 | 2004-05-25 | G.D. Searle, Llc | Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake |
| GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
| DE102005033099A1 (de) | 2005-07-15 | 2007-01-18 | Sanofi-Aventis Deutschland Gmbh | Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung |
-
2006
- 2006-11-14 DE DE102006053635A patent/DE102006053635B4/de not_active Expired - Fee Related
-
2007
- 2007-10-30 PT PT07819434T patent/PT2084172E/pt unknown
- 2007-10-30 HR HR20110197T patent/HRP20110197T1/hr unknown
- 2007-10-30 NZ NZ576762A patent/NZ576762A/en unknown
- 2007-10-30 MY MYPI20091688A patent/MY148429A/en unknown
- 2007-10-30 CA CA2865332A patent/CA2865332C/en active Active
- 2007-10-30 JP JP2009536625A patent/JP5301453B2/ja active Active
- 2007-10-30 ES ES07819434T patent/ES2358371T3/es active Active
- 2007-10-30 AT AT07819434T patent/ATE492554T1/de active
- 2007-10-30 NO NO20091893A patent/NO342236B1/no unknown
- 2007-10-30 KR KR1020097009914A patent/KR101489168B1/ko active Active
- 2007-10-30 CN CN2007800424399A patent/CN101535326B/zh active Active
- 2007-10-30 DE DE502007006055T patent/DE502007006055D1/de active Active
- 2007-10-30 EP EP07819434A patent/EP2084172B1/de active Active
- 2007-10-30 SI SI200730487T patent/SI2084172T1/sl unknown
- 2007-10-30 CA CA2669230A patent/CA2669230C/en active Active
- 2007-10-30 BR BRPI0718813A patent/BRPI0718813B8/pt active IP Right Grant
- 2007-10-30 PL PL07819434T patent/PL2084172T3/pl unknown
- 2007-10-30 RU RU2009122470/04A patent/RU2456282C2/ru active
- 2007-10-30 DK DK07819434.7T patent/DK2084172T3/da active
- 2007-10-30 WO PCT/EP2007/009393 patent/WO2008058628A1/de not_active Ceased
- 2007-10-30 MX MX2009003958A patent/MX2009003958A/es active IP Right Grant
- 2007-10-30 AU AU2007321496A patent/AU2007321496B2/en active Active
- 2007-11-12 UY UY30709A patent/UY30709A1/es unknown
- 2007-11-12 PE PE2007001553A patent/PE20081493A1/es not_active Application Discontinuation
- 2007-11-12 AR ARP070105027A patent/AR063786A1/es active IP Right Grant
- 2007-11-12 TW TW096142599A patent/TWI414530B/zh active
- 2007-11-13 CL CL200703262A patent/CL2007003262A1/es unknown
-
2009
- 2009-04-03 SV SV2009003216A patent/SV2009003216A/es unknown
- 2009-04-20 CR CR10733A patent/CR10733A/es not_active Application Discontinuation
- 2009-05-04 NI NI200900076A patent/NI200900076A/es unknown
- 2009-05-06 CO CO09045559A patent/CO6190534A2/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000180A patent/TN2009000180A1/fr unknown
- 2009-05-12 MA MA31864A patent/MA30883B1/fr unknown
- 2009-05-12 IL IL198718A patent/IL198718A/en active IP Right Grant
- 2009-05-13 EC EC2009009327A patent/ECSP099327A/es unknown
- 2009-05-13 GT GT200900125A patent/GT200900125A/es unknown
- 2009-05-14 US US12/465,911 patent/US7956085B2/en active Active
-
2011
- 2011-02-04 CY CY20111100133T patent/CY1111166T1/el unknown
-
2017
- 2017-07-12 AR ARP170101938A patent/AR109033A2/es unknown
-
2018
- 2018-04-11 NO NO20180497A patent/NO344589B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109033A2 (es) | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso | |
| ES2486267T3 (es) | 2-(Fenil 2-fluoro-substituido)-6-amino-5-cloro-4-pirimidinacarboxilatos y su uso como herbicidas | |
| ECSP067077A (es) | Derivados de pirrolopiridina y su uso como antagonistas de crth2 | |
| ECSP055853A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, productos farmaceuticos que contienen dichos compuestos, y el uso de los mismos | |
| DOP2015000014A (es) | Derivados de azaadamantano y metodos de uso de los mismos | |
| AR111425A2 (es) | MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN | |
| ECSP10010693A (es) | Compuestos pirazólicos 436 | |
| CO6241107A2 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento | |
| CO6160235A2 (es) | Isoxazolinas insecticidas | |
| DOP2007000092A (es) | Derivados de cicloalquilaminoácidos | |
| AR038326A1 (es) | Antibacterianos feniloxazolidinonas sustituidos con heterociclicos biciclicos y composiciones relacionadas y metodos | |
| NI201000179A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
| UY28764A1 (es) | Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico | |
| AR105340A2 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden | |
| ECSP12011867A (es) | Derivados bencimidazol-imidazol | |
| AR068479A1 (es) | (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica | |
| SV2009003281A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa.0 | |
| UY28342A1 (es) | Nuevos compuestos | |
| AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
| ECSP077402A (es) | Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica | |
| AR052266A1 (es) | Derivados de pirroles, su preparacion, y su uso como compuestos farmaceuticos | |
| ECSP10010265A (es) | Sales farmaceuticamente aceptables de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8 dihidro-9h-purin-9-il)propil](3-morfolin-4 ilpropil)amino]metil}fenil) | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| UY27853A1 (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |